Most Clicked StoriesMore >


Diabetes drug from Lilly, Boehringer gains expanded FDA approval

DiabetesPro SmartBrief | Jul 22, 2016

Boehringer Ingelheim and Eli Lilly and Co.'s combination drug Synjardy, or empagliflozin/metformin hydrochloride, has received expanded approval from the FDA as an adjunctive treatment, along with diet and exercise, to improve glycemic control in adult type 2 diabetes patients who have not received prior treatment. The approval was backed by positive results from a late-stage study. Endocrinology Advisor (07/19)


Hypoglycemia ups CVD, mortality risk in diabetes, study finds

DiabetesPro SmartBrief | Jul 21, 2016

Type 1 diabetes progression tied to elevations in PI:C ratio, study finds

DiabetesPro SmartBrief | Jul 20, 2016

Study: Diabetes drug classes have similar CVD, all-cause mortality risks

DiabetesPro SmartBrief | Jul 21, 2016

Researchers examine mortality rate among DKA patients

DiabetesPro SmartBrief | Jul 19, 2016

Food app goes beyond analyzing nutrition labels

DiabetesPro SmartBrief | Jul 20, 2016

UK study shows increase in hospital admissions for hypoglycemia

DiabetesPro SmartBrief | Jul 19, 2016

90% of strokes are preventable, research shows

DiabetesPro SmartBrief | Jul 19, 2016

Continuing education for health care professionals who treat patients with diabetes

DiabetesPro SmartBrief | Jul 20, 2016

Free online materials for patient education

DiabetesPro SmartBrief | Jul 21, 2016


Find DiabetesPro SmartBrief Issues by Date:



ADA News More >


Free online materials for patient education

DiabetesPro SmartBrief | Jul 21, 2016

Continuing education for health care professionals who treat patients with diabetes

DiabetesPro SmartBrief | Jul 20, 2016

Association offers free Back to School webinar for parents on July 21, 2-3 p.m. ET

DiabetesPro SmartBrief | Jul 19, 2016

Become a recognized education program through the American Diabetes Association

DiabetesPro SmartBrief | Jul 08, 2016

Child Care Setting: The Rights of Children with Diabetes

DiabetesPro SmartBrief | Jul 07, 2016




Sign up for DiabetesPro SmartBrief



Designed specifically for health care professionals, DiabetesPro SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news, trends, and technology updates that matter most to health care professionals. Learn more

Recent Poll view more polls


Poll: Do you think a glucose-sensing contact lens would be of benefit to your patients?

Chart.